logo-loader
RNS
ProBiotix Health PLC

Probiotix Health PLC - New Commercial Partnership in Australia

RNS Number : 9281D
Probiotix Health PLC
20 October 2025
 

20 October 2025

 

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

New Commercial Partnership in Australia

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Australia based Wellizen.

 

Wellizen is an innovation-driven wellness consumer brand company with a focus on health solutions in nutrition, microbiome and lifestyle wellness. Headquartered in Sydney, Australia, it has operations across New Zealand, Southeast Asia, North America and the Middle East. Wellizen has successfully established its consumer brand THERONOMIC® as a market leader in the precision biotic supplement consumer space. 

 

ProBiotix will supply LPLDL® for local manufacturing of a new innovative dietary supplement capsule product targeting cardiometabolic health: Tri-Biotic Cardi-Flo, introduced under the THERONOMIC® brand. The commercial rollout will take place in October this year, with an initial launch in Singapore through Wellizen's direct retail consumer e-commerce platform, followed by a late October direct to consumer launch in Australia. Additional market entries across New Zealand, Southeast Asia and other Asian markets are planned for the coming months as part of a phased regional expansion strategy. Potential future channels include business to business pharmacy distribution across Australia, New Zealand, Dubai, and the wider Middle East.

 

The nutraceutical segment addressing cardiometabolic health is experiencing strong growth across all the target regions, with market expansion rates of 8-10% annually*, driven by rising lifestyle-related health concerns and demand for clinically supported, science-based preventive product solutions.

 

Steen Andersen, CEO of ProBiotix, commented: "The use of our clinically proven LPLDL® by Wellizen to complement their existing THERONOMIC®consumer product range, marks a significant step for ProBiotix. It further validates the increasing application of our innovative technology to target those suffering with high cholesterol, and we are very excited about its future sales potential.

 

"High cholesterol affects an estimated 30-48% of adults in Southeast Asia, around 30% in Australia, and nearly one-third of adults across the Middle East, representing a major and fast-growing cardiometabolic health challenge globally**."

 

Julie Chen, Head of R&D of THERONOMIC®, added: "We're excited to launch THERONOMIC® Cardi-Flo as part of our ongoing mission to deliver science-backed solutions that address health at its root through the gut.

 

"This product showcases our innovative Tribiotic® platform and features LPLDL®, a clinically studied probiotic strain with proven benefits for cardiometabolic health. Our partnership with ProBiotix reflects a shared commitment to advancing microbiome science, and we are confident Cardi-Flo will bring meaningful impact to consumers seeking natural, evidence-based support for heart health."

 

*Source: Precedence Research - Asia Pacific Cardiovascular Health Supplements Market (2025-2034), Grand View Research - Asia Pacific Cardiovascular Health Supplements Market Size & Outlook (2025-2030)

**Source: Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region" by Lee et al., 2021 and Australian Bureau of Statistics (ABS) - National Health Measures Survey, 2022-24

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

 

investors@probiotixhealth.com

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

 



Peterhouse Capital Limited

Aquis Corporate Adviser and Broker

 

 

 

Mark Anwyl

Duncan Vasey

 

Tel: 020 7469 0930

 


This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

Notes to Editors:

 

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

 

The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXMLBLTMTMBMLA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read